FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:242-254 July 24, 1997 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Approximately 95 percent of malignant tumors arising in the testis are germ-cell tumors, a term that indicates their origin in primordial germ cells. Germ-cell tumors also occasionally arise in extragonadal primary sites, and their management follows that of testicular germ-cell tumors. More than 90 percent of patients with newly diagnosed germ-cell tumors are cured, and delay in diagnosis correlates with a higher stage at presentation for treatment.^1,2 Management has changed substantially in the past 20 years, largely because of the ability of cisplatin-containing combination chemotherapy to cure advanced disease.³ In this review, we discuss recent developments in our understanding of . . . [Full Text of this Article]

Epidemiology

Histology and Tumor Biology

Histology

Genetics

Immunohistochemical Markers

Diagnosis

Clinical Presentation

Pattern of Metastases

Radiographic Evaluation

Serum Tumor Markers

Classification of Disease Stages

Therapy for Low-Stage Germ-Cell Tumors

Seminoma

Stage I Nonseminomatous Tumor

Stage II Nonseminomatous Tumor

Chemotherapy for Advanced Disease

Good-Risk Patients

Poor-Risk Patients

Surgery after Chemotherapy

Second- and Third-Line Chemotherapy

Treatment Sequelae

Midline Tumors of Uncertain Histogenesis

Source Information

From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Department of Medicine, Cornell University Medical College, New York.

Address reprint requests to Dr. Bosl at Memorial Hospital, 1275 York Ave., New York, NY 10021.

References

This article has been cited by other articles:

• Sheinfeld, J., Motzer, R. J. (2008). Stage I Testicular Cancer Management and Necessity for Surgical Expertise. JCO 26: 2934-2936 [Full Text]  
• Bokemeyer, C., Oechsle, K., Honecker, F., Mayer, F., Hartmann, J. T., Waller, C. F., Bohlke, I., Kollmannsberger, C. (2008). Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19: 448-453 [Abstract] [Full Text]  
• Martin, L. P., Hamilton, T. C., Schilder, R. J. (2008). Platinum Resistance: The Role of DNA Repair Pathways. Clin. Cancer Res. 14: 1291-1295 [Abstract] [Full Text]  
• Culine, S., Kramar, A., Theodore, C., Geoffrois, L., Chevreau, C., Biron, P., Nguyen, B. B., Heron, J.-F., Kerbrat, P., Caty, A., Delva, R., Fargeot, P., Fizazi, K., Bouzy, J., Droz, J.-P. (2008). Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. JCO 26: 421-427 [Abstract] [Full Text]  
• Hartmann, J. T., Gauler, T., Metzner, B., Gerl, A., Casper, J., Rick, O., Horger, M., Schleicher, J., Derigs, G., Mayer-Steinacker, R., Beyer, J., Kuczyk, M. A., Bokemeyer, C. (2007). Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group. JCO 25: 5742-5747 [Abstract] [Full Text]  
• de Wit, R. (2007). Optimal Management of Retroperitoneal Metastatic Nonseminomatous Testicular Cancer: Toward a Better Selection Between Scalpel and Needle. JCO 25: 5550-5552 [Full Text]  
• Stephenson, A. J., Bosl, G. J., Motzer, R. J., Bajorin, D. F., Stasi, J. P., Sheinfeld, J. (2007). Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. JCO 25: 5597-5602 [Abstract] [Full Text]  
• Khan, O., Protheroe, A. (2007). Testis cancer. Postgrad. Med. J. 83: 624-632 [Abstract] [Full Text]  
• Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., Abonour, R. (2007). High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors. NEJM 357: 340-348 [Abstract] [Full Text]  
• Culine, S, Kerbrat, P, Kramar, A, Theodore, C, Chevreau, C, Geoffrois, L, Bui, N., Peny, J, Caty, A, Delva, R, Biron, P, Fizazi, K, Bouzy, J, Droz, J. (2007). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18: 917-924 [Abstract] [Full Text]  
• Mathew, R. M., Vandenberghe, R., Garcia-Merino, A., Yamamoto, T., Landolfi, J. C., Rosenfeld, M. R., Rossi, J. E., Thiessen, B., Dropcho, E. J., Dalmau, J. (2007). Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 68: 900-905 [Abstract] [Full Text]  
• Einhorn, L. H., Brames, M. J., Juliar, B., Williams, S. D. (2007). Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant. JCO 25: 513-516 [Abstract] [Full Text]  
• Kondagunta, G. V., Bacik, J., Sheinfeld, J., Bajorin, D., Bains, M., Reich, L., Deluca, J., Budnick, A., Ishill, N., Mazumdar, M., Bosl, G. J., Motzer, R. J. (2007). Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. JCO 25: 85-90 [Abstract] [Full Text]  
• Bajorin, D. F., Motzer, R. J., Bosl, G. J. (2006). Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. JCO 24: 5479-5481 [Full Text]  
• de Wit, R., Fizazi, K. (2006). Controversies in the Management of Clinical Stage I Testis Cancer. JCO 24: 5482-5492 [Abstract] [Full Text]  
• Kondagunta, G. V., Motzer, R. J. (2006). Chemotherapy for Advanced Germ Cell Tumors. JCO 24: 5493-5502 [Abstract] [Full Text]  
• Li, D., Han, X. (2006). Evaluation of toxicity of methyl tert-butyl ether (MTBE) on mouse spermatogenic cells in vitro. Toxicol Ind Health 22: 291-299 [Abstract]  
• Korkola, J. E., Houldsworth, J., Chadalavada, R. S.V., Olshen, A. B., Dobrzynski, D., Reuter, V. E., Bosl, G. J., Chaganti, R.S.K. (2006). Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors. Cancer Res. 66: 820-827 [Abstract] [Full Text]  
• Travis, L. B., Fossa, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., Andersson, M., Kaijser, M., Gospodarowicz, M., Joensuu, T., Cohen, R. J., Boice, J. D. Jr., Dores, G. M., Gilbert, E. S. (2005). Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors. JNCI J Natl Cancer Inst 97: 1354-1365 [Abstract] [Full Text]  
• Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., Motzer, R. J. (2005). Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. JCO 23: 6549-6555 [Abstract] [Full Text]  
• McIntyre, A., Summersgill, B., Grygalewicz, B., Gillis, A. J.M., Stoop, J., van Gurp, R. J.H.L.M., Dennis, N., Fisher, C., Huddart, R., Cooper, C., Clark, J., Oosterhuis, J. W., Looijenga, L. H.J., Shipley, J. (2005). Amplification and Overexpression of the KIT Gene Is Associated with Progression in the Seminoma Subtype of Testicular Germ Cell Tumors of Adolescents and Adults. Cancer Res. 65: 8085-8089 [Abstract] [Full Text]  
• Garolla, A, Ferlin, A, Vinanzi, C, Roverato, A, Sotti, G, Artibani, W, Foresta, C (2005). Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer 12: 645-655 [Abstract] [Full Text]  
• Kesler, K. A., Wilson, J. L., Cosgrove, J. A., Brooks, J. A., Messiha, A., Fineberg, N. S., Einhorn, L. H., Brown, J. W. (2005). Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: Analysis of a single-institution experience. J. Thorac. Cardiovasc. Surg. 130: 408-415 [Abstract] [Full Text]  
• Fossa, S. D., Chen, J., Schonfeld, S. J., McGlynn, K. A., McMaster, M. L., Gail, M. H., Travis, L. B. (2005). Risk of Contralateral Testicular Cancer: A Population-based Study of 29 515 U.S. Men. JNCI J Natl Cancer Inst 97: 1056-1066 [Abstract] [Full Text]  
• Stephenson, A. J., Bosl, G. J., Motzer, R. J., Kattan, M. W., Stasi, J., Bajorin, D. F., Sheinfeld, J. (2005). Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. JCO 23: 2781-2788 [Abstract] [Full Text]  
• Lotz, J.-P., Bui, B., Gomez, F., Theodore, C., Caty, A., Fizazi, K., Gravis, G., Delva, R., Peny, J., Viens, P., Duclos, B., De Revel, T., Cure, H., Gligorov, J., Guillemaut, S., Segura, C., Provent, S., Droz, J.-P., Culine, S., Biron, P., On behalf of the Groupe d'Etudes des Tumeurs Uro-G, (2005). Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 16: 411-418 [Abstract] [Full Text]  
• Fizazi, K., Culine, S., Kramar, A., Amato, R. J., Bouzy, J., Chen, I., Droz, J.-P., Logothetis, C. J. (2004). Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors. JCO 22: 3868-3876 [Abstract] [Full Text]  
• Shabbir, M., Morgan, R. J (2004). Testicular cancer. The Journal of the Royal Society for the Promotion of Health 124: 217-218 [Abstract]  
• van Dijk, M. R., Steyerberg, E. W., Stenning, S. P., Habbema, J. D. F. (2004). Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: a validation study. Ann Oncol 15: 1400-1405 [Abstract] [Full Text]  
• Kamai, T., Yamanishi, T., Shirataki, H., Takagi, K., Asami, H., Ito, Y., Yoshida, K.-I. (2004). Overexpression of RhoA, Rac1, and Cdc42 GTPases Is Associated with Progression in Testicular Cancer. Clin. Cancer Res. 10: 4799-4805 [Abstract] [Full Text]  
• Stenman, U.-H. (2004). Standardization of Assays for Human Chorionic Gonadotropin. Clin. Chem. 50: 798-800 [Full Text]  
• Schneider, B. P., Kesler, K. A., Brooks, J. A., Yiannoutsos, C., Einhorn, L. H. (2004). Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer. JCO 22: 1195-1200 [Abstract] [Full Text]  
• Pectasides, D., Pectasides, M., Farmakis, D., Aravantinos, G., Nikolaou, M., Koumpou, M., Gaglia, A., Kostopoulou, V., Mylonakis, N., Skarlos, D. (2004). Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15: 493-497 [Abstract] [Full Text]  
• Kondagunta, G. V., Sheinfeld, J., Mazumdar, M., Mariani, T. V., Bajorin, D., Bacik, J., Bosl, G. J., Motzer, R. J. (2004). Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. JCO 22: 464-467 [Abstract] [Full Text]  
• Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Hartmann, J.T., Rick, O., Stengele, K., Hohloch, K., Spott, C., Kanz, L., Bokemeyer, C. (2004). Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group. JCO 22: 108-114 [Abstract] [Full Text]  
• Vergouwe, Y., Steyerberg, E. W., Eijkemans, M. J.C., Albers, P., Habbema, J. D. F. (2003). Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review. JCO 21: 4092-4099 [Abstract] [Full Text]  
• Motzer, R. J., Sheinfeld, J. (2003). Poor-Risk Testicular Cancer and High-Dose Chemotherapy. JCO 21: 4073-4074 [Full Text]  
• Schmoll, H.-J., Kollmannsberger, C., Metzner, B., Hartmann, J.T., Schleucher, N., Schoffski, P., Schleicher, J., Rick, O., Beyer, J., Hossfeld, D., Kanz, L., Berdel, W.E., Andreesen, R., Bokemeyer, C. (2003). Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group. JCO 21: 4083-4091 [Abstract] [Full Text]  
• Mazumdar, M., Bacik, J., Tickoo, S. K., Dobrzynski, D., Donadio, A., Bajorin, D., Motzer, R., Reuter, V., Bosl, G. J. (2003). Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. JCO 21: 2679-2688 [Abstract] [Full Text]  
• Madani, A., Kemmer, K., Sweeney, C., Corless, C., Ulbright, T., Heinrich, M., Einhorn, L. (2003). Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 14: 873-880 [Abstract] [Full Text]  
• Powles, T., Bower, M., Daugaard, G., Shamash, J., De Ruiter, A., Johnson, M., Fisher, M., Anderson, J., Mandalia, S., Stebbing, J., Nelson, M., Gazzard, B., Oliver, T. (2003). Multicenter Study of Human Immunodeficiency Virus-Related Germ Cell Tumors. JCO 21: 1922-1927 [Abstract] [Full Text]  
• Kesler, K. A., Brooks, J. A., Rieger, K. M., Fineberg, N. S., Einhorn, L. H., Brown, J. W. (2003). Mediastinal metastases from testicular nonseminomatous germ cell tumors: Patterns of dissemination and predictors of long-term survival with surgery. J. Thorac. Cardiovasc. Surg. 125: 913-923 [Abstract] [Full Text]  
• Lutke Holzik, M. F., Hoekstra, H. J., Mulder, N. H., Suurmeijer, A. J. H., Sleijfer, D. Th., Gietema, J. A. (2003). Non-Germ Cell Malignancy in Residual or Recurrent Mass After Chemotherapy for Nonseminomatous Testicular Germ Cell Tumor. Ann. Surg. Oncol. 10: 131-135 [Abstract] [Full Text]  
• Mayer, F., Stoop, H., Scheffer, G. L., Scheper, R., Oosterhuis, J. W., Looijenga, L. H. J., Bokemeyer, C. (2003). Molecular Determinants of Treatment Response in Human Germ Cell Tumors. Clin. Cancer Res. 9: 767-773 [Abstract] [Full Text]  
• Mueller, T., Voigt, W., Simon, H., Fruehauf, A., Bulankin, A., Grothey, A., Schmoll, H.-J. (2003). Failure of Activation of Caspase-9 Induces a Higher Threshold for Apoptosis and Cisplatin Resistance in Testicular Cancer. Cancer Res. 63: 513-521 [Abstract] [Full Text]  
• Wei, M., Burenkova, O., Lippard, S. J. (2003). Cisplatin Sensitivity in Hmgb1-/- and Hmgb1+/+ Mouse Cells. J. Biol. Chem. 278: 1769-1773 [Abstract] [Full Text]  
• George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., Gobbett, T. A., Heiber, D. J., Heerema, N. A., Ramsey, H. C., Thurston, V. C., Jung, S.-H., Shen, J., Finch, D. E., Kelley, M. R., Einhorn, L. H. (2003). Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis. JCO 21: 113-122 [Abstract] [Full Text]  
• Gietema, J. A., Meinardi, M. T., Sleijfer, D. T., Hoekstra, H. J., van der Graaf, W. T. A. (2002). Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 13: 1616-1620 [Abstract] [Full Text]  
• Hartmann, J. T., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Fossa, S. D., Beyer, J., Pont, J., Kanz, L., Einhorn, L., Bokemeyer, C. (2002). Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13: 1017-1028 [Abstract] [Full Text]  
• Kollmannsberger, C., Rick, O., Derigs, H.-G., Schleucher, N., Schoffski, P., Beyer, J., Schoch, R., Sayer, H.G., Gerl, A., Kuczyk, M., Spott, C., Kanz, L., Bokemeyer, C. (2002). Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group. JCO 20: 2031-2037 [Abstract] [Full Text]  
• Hinton, S., Catalano, P., Einhorn, L. H., Loehrer, P. J. Sr, Kuzel, T., Vaughn, D., Wilding, G. (2002). Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group. JCO 20: 1859-1863 [Abstract] [Full Text]  
• Bokemeyer, C., Nichols, C. R., Droz, J.-P., Schmoll, H.-J., Horwich, A., Gerl, A., Fossa, S. D., Beyer, J., Pont, J., Kanz, L., Einhorn, L., Hartmann, J. T. (2002). Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis. JCO 20: 1864-1873 [Abstract] [Full Text]  
• Beyer, J., Stenning, S., Gerl, A., Fossa, S., Siegert, W. (2002). High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13: 599-605 [Abstract] [Full Text]  
• Kersemaekers, A.-M. F., Mayer, F., Molier, M., van Weeren, P. C., Oosterhuis, J. W., Bokemeyer, C., Looijenga, L. H.J. (2002). Role of P53 and MDM2 in Treatment Response of Human Germ Cell Tumors. JCO 20: 1551-1561 [Abstract] [Full Text]  
• Fizazi, K., Do, K.-A., Wang, X., Finn, L., Logothetis, C. J., Amato, R. J. (2002). A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol 13: 125-134 [Abstract] [Full Text]  
• Vuky, J., Tickoo, S. K., Sheinfeld, J., Bacik, J., Amsterdam, A., Mazumdar, M., Reuter, V., Bajorin, D. F., Bosl, G. J., Motzer, R. J. (2002). Salvage Chemotherapy for Patients With Advanced Pure Seminoma. JCO 20: 297-301 [Abstract] [Full Text]  
• Tickoo, S. K., Hutchinson, B., Bacik, J., Mazumdar, M., Motzer, R. J., Bajorin, D. F., Bosl, G. J., Reuter, V. E. (2002). Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. INT J SURG PATHOL 10: 23-32 [Abstract]  
• Hartmann, J. T., Fossa, S. D., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Beyer, J., Pont, J., Fizazi, K., Hecker, H., Kanz, L., Einhorn, L., Bokemeyer, C. (2001). Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors. JNCI J Natl Cancer Inst 93: 1733-1738 [Abstract] [Full Text]  
• Moroni, M., Veronese, S., Schiavo, R., Carminati, O., Sorensen, B. S., Gambacorta, M., Siena, S. (2001). Epidermal Growth Factor Receptor Expression and Activation in Nonseminomatous Germ Cell Tumors. Clin. Cancer Res. 7: 2770-2775 [Abstract] [Full Text]  
• Bokemeyer, C., Gillis, A. J.M., Pompe, K., Mayer, F., Metzner, B., Schleucher, N., Schleicher, J., Pflugrad-Jauch, G., Oosterhuis, J. W., Kanz, L., Looijenga, L. H.J. (2001). Clinical Impact of Germ Cell Tumor Cells in Apheresis Products of Patients Receiving High-Dose Chemotherapy. JCO 19: 3029-3036 [Abstract] [Full Text]  
• Fizazi, K., Tjulandin, S., Salvioni, R., Germa-Lluch, J. R., Bouzy, J., Ragan, D., Bokemeyer, C., Gerl, A., Flechon, A., de Bono, J. S., Stenning, S., Horwich, A., Pont, J., Albers, P., De Giorgi, U., Bower, M., Bulanov, A., Pizzocaro, G., Aparicio, J., Nichols, C. R., Theodore, C., Hartmann, J. T., Schmoll, H.-J., Kaye, S. B., Culine, S., Droz, J.-P., Mahe, C. (2001). Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy--Results From an International Study Group. JCO 19: 2647-2657 [Abstract] [Full Text]  
• Mazumdar, M., Bajorin, D.F., Bacik, J., Higgins, G., Motzer, R.J., Bosl, G.J. (2001). Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy. JCO 19: 2534-2541 [Abstract] [Full Text]  
• Rabbani, F., Sheinfeld, J., Farivar-Mohseni, H., Leon, A., Rentzepis, M. J., Reuter, V. E., Herr, H. W., McCaffrey, J. A., Motzer, R. J., Bajorin, D. F., Bosl, G. J. (2001). Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. JCO 19: 2020-2025 [Abstract] [Full Text]  
• Hartmann, J. T., Einhorn, L., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Fossa, S. D., Beyer, J., Pont, J., Schmoll, H.-J., Kanz, L., Bokemeyer, C. (2001). Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis. JCO 19: 1641-1648 [Abstract] [Full Text]  
• Hildebrandt, M., Rick, O., Salama, A., Siegert, W., Huhn, D., Beyer, J. (2000). Detection of Germ-Cell Tumor Cells in Peripheral Blood Progenitor Cell Harvests: Impact on Clinical Outcome. Clin. Cancer Res. 6: 4641-4646 [Abstract] [Full Text]  
• Travis, L. B., Andersson, M., Gospodarowicz, M., van Leeuwen, F. E., Bergfeldt, K., Lynch, C. F., Curtis, R. E., Kohler, B. A., Wiklund, T., Storm, H., Holowaty, E., Hall, P., Pukkala, E., Sleijfer, D. T., Clarke, E. A., Boice, J. D. Jr., Stovall, M., Gilbert, E. (2000). Treatment-Associated Leukemia Following Testicular Cancer. JNCI J Natl Cancer Inst 92: 1165-1171 [Abstract] [Full Text]  
• Motzer, R. J., Sheinfeld, J., Mazumdar, M., Bains, M., Mariani, T., Bacik, J., Bajorin, D., Bosl, G. J. (2000). Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. JCO 18: 2413-2418 [Abstract] [Full Text]  
• Steyerberg, E. W., Keizer, H. J., Sleijfer, D. T., Fosså, S. D., Bajorin, D. F., Gerl, A., de Wit, R., Kirkels, W. J., Koops, H. S., Habbema, J. D. F. (2000). Retroperitoneal Metastases in Testicular Cancer: Role of CT Measurements of Residual Masses in Decision Making for Resection after Chemotherapy. Radiology 215: 437-444 [Abstract] [Full Text]  
• Baou, N., Bouras, M., Droz, J.-P., Benahmed, M., Krantic, S. (2000). Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type. Carcinogenesis 21: 805-810 [Abstract] [Full Text]  
• Motzer, R. J., Mazumdar, M., Sheinfeld, J., Bajorin, D. F., Macapinlac, H. A., Bains, M., Reich, L., Flombaum, C., Mariani, T., Tong, W. P., Bosl, G. J. (2000). Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. JCO 18: 1173-1180 [Abstract] [Full Text]  
• Chaganti, R. S. K., Houldsworth, J. (2000). Genetics and Biology of Adult Human Male Germ Cell Tumors. Cancer Res. 60: 1475-1482 [Abstract] [Full Text]  
• Sweeney, C. J., Hermans, B. P., Heilman, D. K., Foster, R. S., Donohue, J. P., Einhorn, L. H. (2000). Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma-Predominant Testis Cancer. JCO 18: 358-358 [Abstract] [Full Text]  
• Jaster, J. H., Monkemuller, K. E., Wingerchuk, D. M., Noseworthy, J. H., Kimmel, D. W. (1999). Paraneoplastic disorders associated with seminoma. Neurology 53: 656-656 [Full Text]  
• Collette, L., Sylvester, R. J., Stenning, S. P., Fossa, S. D., Mead, G. M., de Wit, R., de Mulder, P. H. M., Neymark, N., Lallemand, E., Kaye, S. B. (1999). Impact of the Treating Institution on Survival of Patients With "Poor-Prognosis" Metastatic Nonseminoma. JNCI J Natl Cancer Inst 91: 839-846 [Abstract] [Full Text]  
• Einhorn, L. H., Stender, M. J., Williams, S. D. (1999). Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors. JCO 17: 509-509 [Abstract] [Full Text]  
• Bokemeyer, C., Gerl, A., Schoffski, P., Harstrick, A., Niederle, N., Beyer, J., Casper, J., Schmoll, H.J., Kanz, L. (1999). Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer. JCO 17: 512-512 [Abstract] [Full Text]  
• Roelofs, H., van Gurp, R. J. H. L. M., Oosterhuis, J. W., Looijenga, L. H. J. (1998). Detection of Human Endogenous Retrovirus Type K-Specific Transcripts in Testicular Parenchyma and Testicular Germ Cell Tumors of Adolescents and Adults : Clinical and Biological Implications. Am. J. Pathol. 153: 1277-1282 [Abstract] [Full Text]  
• Zamble, D. B., Jacks, T., Lippard, S. J. (1998). p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. USA 95: 6163-6168 [Abstract] [Full Text]